Please assess the completion status of the following clinical trial:

Trial Title: Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature,~* age ≥18,~  * Group A Detoxification of stimulants (cocaine, amphetamine and/or methamphetamine); ICD-10: F14.2 and/or F15.2) OR Stable opioid dependency (no parallel consumption). Detoxifica-tion of stimulants.~ * Group B Opioid dependency and dependency of stimulants (cocaine, amphetamine and/or methamphetamine) and Detoxification of parallel consumption of stimulants and heroin (ICD-10: F11.2, 14.2, 15.2)~* admission for detoxification to ward U2 of the University Psychiatric Hospital of Basel~Exclusion Criteria:~* contraindications to the class of drugs under study or to any of the excipients, e.g. known hypersensitivity or allergy to class of drugs or the investigational product;~* acute or severe co-morbid psychiatric disturbances (such as a heavy episode of major depression with suicidal ideations, acute exacerbation of a bipolar disorder, acute exacerbation of schizophrenia, alcohol addiction with an acute relapse, psychosis, dementia);~* current medical conditions excluding participation (such as acute infectious disease, moni-tored by elevated CRP, diabetes mellitus, anticoagulation therapy);~* recent history of systemic or topic glucocorticoid therapy;~* alcohol intake \> 0.0 ‰ according to breathalyser test on day 0 (screening) to exclude severe alcohol abuse;~* specific drugs not allowed during the study or for specific periods of time prior to the administration of the test dose: Anticoagulant agents, antidiabetic agents, cyclosporine;~* women who are pregnant or breast feeding;~* intention to become pregnant during the course of the study;~* inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia;~* participation in another study with investigational drug within the 30 days preceding or during the present study;~* previous enrolment into the current study;~* enrolment of the investigator, his/her family members, employees and other dependent persons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Prednisolon (Type: EXPERIMENTAL): Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
- Placebo (Type: PLACEBO_COMPARATOR): Identical looking capsules like the IMP containing placebo (without active component) for oral administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).